

Serial No. 09/827,255
Attorney Docket No. 32144183-001336

PATENT

PLEASE AMEND THE APPLICATION AS FOLLOWS IN THE CLAIMS SUBMITTED
IN THE ATTACHED SHEET LABELED LISTING OF CLAIMS.

REMARKS

Claims 1-7 and 9 are currently pending in this application. Claim 10 has been withdrawn, without prejudice. Applicants' preserve the right to file a divisional application on non-elected subject matter. Claims 1 and 9 have been amended. Support is found on page 4, lines 20-24 and page 7, lines 19-21 and Examples in the specification. No new matter has been introduced. Entry of the following amendment and reconsideration are respectfully requested.

Rejection under §112, 1st ¶

Applicants believe the rejection under the first paragraph of §112 is moot.
Withdrawal of the §112, 1st ¶ is respectfully requested.

CONCLUSION

Applicants respectfully request reconsideration and allowance of all claims. If the Examiner has any questions or other correspondence regarding this application, Applicants request that Examiner contact the Applicants' attorney at the change of correspondence at the below-listed telephone number and overseas address. An one month petition for extension of time accompanies this response. It is believed no additional fees are

Serial No. 09/827,255
Attorney Docket No. 32144183-001336

PATENT

required to be paid at this time, however, in the event any other fee is due, authorization to charge deposit account no. 50-2497 (Attorney Docket No. 32144183-001336) is provided.

Favorable action is respectfully requested.

Respectfully submitted,


BAKER & MCKENZIE



YUN, Caroline J.
Reg. No. 34,952

June 5, 2003
Caroline J. Yun
BAKER & MCKENZIE
14th Floor, Hutchison House
10 Harcourt Road, Central
Hong Kong SAR
(852) 2846 1800 (general)
(852) 2846 2453 (direct)
(852) 2845 0476 (facsimile)
caroline.j.yun@bakernet.com

LISTING OF CLAIMS

- 
1. (currently amended): A composition for the targeted delivery of a therapeutic agent to a tissue expressing asialoglycoprotein receptors comprising an effective amount of the agent encapsulated in a liposome having a molar ratio PC:Chol:PS of 11:4:0.025 coupled to desialyated glycoprotein- α 1.
 2. (original): The composition of claim 1, wherein the therapeutic agent is a drug or a polynucleotide.
 3. (previously amended): The composition of claim 2, wherein the polynucleotide is selected from the group consisting of cDNA encoding a therapeutic protein, a ribozyme, and antisense DNA.
 4. (previously amended): The composition of claim 1, wherein the therapeutic agent is selected from the group consisting of a cytotoxic drugs and a protein.
 5. (original): The composition of claim 4, wherein the cytotoxic drug is selected from the group consisting of doxorubicin, vincristine, daunorubicin, and amphiphatic amines.
 6. (previously amended): The composition of claim 1, wherein the desialyated glycoprotein - α 1 is coupled to the liposome by an avidin-biotin or thiol-maleamide linkages.
 7. (original): A method for targeted delivery of a therapeutic agent to a tissue expressing asialoglycoprotein receptors comprising delivery to the tissue an effective amount of the composition of any of claims 1 to 6.
 8. (canceled)
 9. (currently amended): A composition for the targeted delivery of a therapeutic agent to a tissue expressing asialoglycoprotein receptors comprising an effective amount of a doxorubicin encapsulated in a liposome having a molar ratio PC:Chol:PS of 11:4:0.025 coupled to desialyated glycoprotein- α 1 by an avidin-biotin linkage.
 10. (withdrawn)
-

Serial No. 09/827,255
Attorney Docket No. 32144183-001336
CJY00572 (Response lodged on June 5, 2003)